1. Clinical Overview of Cagrilintide (AM833)

Molecule: A long-acting amylin analog, structurally similar to human amylin and pramlintide (but significantly improved).

Classification:

Appetite-suppressant peptide
Metabolic hormone analog
Gastric-emptying regulator
Weight-loss intensifier
GLP-1 potentiator

Key Clinical Advantages

Potent appetite suppression
Reduced cravings
Decreased food noise
Reduced gastric emptying rate
Improved satiety signaling
Greater weight-loss synergy when combined with GLP-1 agonists

Unlike GLP-1 receptor agonists alone, Cagrilintide targets amylin signaling, giving a broader and more profound satiety response.

2. Mechanisms of Action

Cagrilintide delivers multi-pathway regulation of appetite and energy intake.

2.1 Amylin Receptor Agonism

Cagrilintide activates AMY1, AMY2, AMY3 receptors and calcitonin receptor complexes. This affects:

Brainstem satiety signaling
Hypothalamic appetite suppression
Meal-size reduction

In clinical trials, amylin analogs significantly reduce caloric intake with minimal conscious effort.

2.2 Gastric Emptying Delay

Slower gastric emptying leads to:

Prolonged fullness
Reduced postprandial hunger
Improved glycemic control

This mechanism is similar to GLP-1s but via an independent hormonal pathway, making combination therapy highly effective.

2.3 Reduction of Hedonic Eating & Reward-Driven Food Intake

Cagrilintide acts on CNS reward centers:

Reduces emotional eating
Reduces cravings
Decreases food obsession ("food noise")

Uniquely valuable for high-reward foods (sugar, carbs), binge-trigger behaviors, and evening overeating.

2.4 Weight-Maintenance Effects

Unlike many weight-loss drugs, Cagrilintide:

Maintains satiety long after weight loss
Helps prevent weight regain
Supports metabolic adaptation

Highly effective for post-GLP-1 maintenance after semaglutide/tirzepatide discontinuation.

2.5 GLP-1 Synergy (Powerful Combination)

When combined with GLP-1 agonists:

Weight loss is more than additive
Appetite suppression deepens
Adherence improves
Metabolic changes intensify

This is currently considered the single most effective pharmacologic pairing for obesity management.

3. Evidence Summary — Clinical Domains of Interest

3.1 Obesity & Medical Weight Loss

In trials, Cagrilintide:

Produces 6–10% weight loss as monotherapy
Produces 15–20%+ when combined with a GLP-1 agonist
Works even in metabolic-resistant patients
Reduces binge-eating behaviors

3.2 GLP-1 Rescue & Plateau Breaking

Ideal for patients who:

Plateaued on semaglutide or tirzepatide
Have persistent appetite despite GLP-1s
Need additional satiety control

3.3 Post-GLP-1 Weight Maintenance

Cagrilintide helps prevent regain by:

Maintaining fullness
Reducing cravings
Stabilizing appetite signals
Preventing rapid gastric emptying rebound

3.4 Type 2 Diabetes & Metabolic Syndrome

Secondary benefits:

Improved glycemic control
Reduced postprandial glucose spikes
Lower insulin resistance

Not a primary treatment—adjunct to comprehensive programs.

3.5 Behavioral & Emotional Eating Control

Cagrilintide helps regulate:

Stress eating
Reward-driven snacking
Nighttime eating
Emotional hunger
Craving cycles

4. Administration Routes & Clinical Protocols

Cagrilintide is administered via subcutaneous injection once weekly.

4.1 Subcutaneous Dosing Protocol

Standard Starting Dose: 0.1 mg SC once weekly

Titration Schedule (increase every 2–4 weeks as tolerated):
Week 1–2: 0.1 mg · Week 3–4: 0.3 mg · Week 5–6: 0.5 mg · Week 7–8+: 0.7 mg
Maximum dose (clinic-specific): 1.2 mg weekly

Typical Therapeutic Range: 0.3–0.7 mg weekly
Advanced Dosing (Specialized Centers): Up to 1.2–2.4 mg weekly for severe obesity (only under advanced clinical supervision)

4.2 Timing Guidelines

Inject once weekly, same day each week
Take with or without food
Combine with structured nutritional planning
Avoid overeating after injections (satiety may be delayed ~30–60 min)

4.3 Combination With GLP-1 or GIP/GLP-1 Agonists

Highest synergy combinations:

Cagrilintide + Semaglutide
Cagrilintide + Tirzepatide
Cagrilintide + Liraglutide

Benefits: 15–25%+ weight reduction, reduced side effects from GLP-1 dose escalation, strongest appetite suppression available clinically.

5. Combination Therapy (Peptide Protocol Portal Synergy)

5.1 Cagrilintide + SLU-PP-332

Thermogenesis + appetite suppression
Excellent for stubborn weight-loss resistance

5.2 Cagrilintide + 1-Amino-1MQ

NNMT inhibition
Enhanced fat oxidation
Metabolic acceleration

5.3 Cagrilintide + MOTS-c

AMPK activation
Mitochondrial efficiency
Exercise tolerance improvement

5.4 Cagrilintide + AOD-9604

Synergistic fat-loss pathways
Useful for GLP-1 plateau periods

5.5 Cagrilintide + NAD+ / SS-31

For fatigue-dominant patients:

Improved mitochondria
Better energy
Reduced metabolic lethargy

6. Clinical Decision Trees

Decision Tree 1 — Is Cagrilintide indicated?

Is appetite control inadequate on lifestyle alone? → YES

Is patient plateauing on semaglutide/tirzepatide? → YES

Is weight maintenance after GLP-1 discontinuation needed? → YES

Does patient struggle with cravings, binge patterns, or food noise? → YES

Severe obesity with metabolic dysfunction? → YES

History of GLP-1 intolerance? → Cagrilintide is often better tolerated

Decision Tree 2 — Appropriate Dosing?

Mild-moderate weight loss goals: → 0.1–0.3 mg weekly

Plateau on GLP-1: → 0.3–0.7 mg weekly

Severe obesity / high appetite drive: → 0.7–1.2 mg weekly

Advanced metabolic program: → Up to 2.4 mg weekly (specialist-supervised)

7. Integrated Treatment Archetypes

Archetype A — GLP-1 Plateau Breaker Protocol

Systemic:

Cagrilintide 0.3–0.5 mg weekly
Semaglutide or tirzepatide
SLU-PP-332
REVIVE™ AM mitochondrial support

Outcome: Renewed weight loss momentum.

Archetype B — Post-GLP-1 Weight-Maintenance Protocol

Systemic:

Cagrilintide 0.1–0.3 mg weekly
MOTS-c or AOD-9604
Nutritional habit reinforcement

Outcome: Prevents weight regain when coming off GLP-1s.

Archetype C — Emotional Eating / Craving Control

Systemic:

Cagrilintide 0.3 mg weekly
Oxytocin PRN for emotional hunger
REBALANCE™ PM for stress chemistry

Outcome: Reduced binge cycles & craving-driven nutrition.

Archetype D — High-BMI Comprehensive Weight-Loss Protocol

Systemic:

Cagrilintide 0.5–1.2 mg weekly
Semaglutide or tirzepatide
SLU-PP-332
1-Amino-1MQ
REVIVE™ for metabolic optimization

Outcome: Deep, sustained fat loss.

8. Expected Clinical Timeline

Week 1Appetite reduction begins

Week 2–4Significant drop in cravings & meal size

Week 4–8Steady fat loss, improved food control

Week 8–12Plateau prevention; metabolic improvement

3–6 monthsPeak body-composition results

Long-termStable weight maintenance

9. Contraindications & Precautions

Absolute Contraindications

Medullary thyroid carcinoma (MTC) history
MEN2 syndrome
Severe GI motility disorders
Pregnancy or breastfeeding

Relative Contraindications

Gallbladder disease
Severe GERD
Pancreatitis history
Diabetic gastroparesis
Underweight patients

10. Adverse Effects

Common:

Nausea
Fullness
Mild constipation
Belching
Decreased appetite
Rare: vomiting

Often milder than GLP-1 agonists.

11. Monitoring

Suggested monitoring:

Weight
Waist circumference
Appetite tracking
Fasting glucose
A1C (diabetics)
GI symptoms
Mood & eating behavior patterns

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Cagrilintide (AM833), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Cagrilintide (AM833) Clinical Reference Guide

1. Lau, J., Bloch, P., Schaffer, L., et al. Discovery and preclinical development of cagrilintide (AM833), a long-acting amylin analogue. Cell Metabolism, 32(1), 110–126 (2020).

2. Ludvik, B., Frias, J. P., Hartvig, H., et al. AM833 (cagrilintide) treatment in people with obesity or overweight: A randomized, double-blind, placebo-controlled, 20-week trial. Lancet, 398(10296), 216–227 (2021).

3. Frias, J. P., Nauck, M. A., Van J., et al. Efficacy and safety of cagrilintide with and without semaglutide in adults with overweight or obesity: A phase-1/2 study. Diabetes Care, 44(7), 1503–1512 (2021).

4. Lau, J., & Knudsen, L. B. Amylin receptor agonists and dual amylin/calcitonin receptor agonists (DACRAs): Mechanisms & pharmacology. Trends in Endocrinology & Metabolism, 29(3), 171–182 (2018).

5. Mack, C. M., Smith, P. A., Blundell, J., Tschöp, M. H. Amylin analogues and DACRA-based therapeutics for obesity and metabolic disease. Nature Reviews Drug Discovery, 19(4), 302–323 (2020).

6. Tschöp, M. H., Finan, B., Müller, T. D., et al. The multi-agonist paradigm: Amylin, GLP-1, GIP, and glucagon pathways in obesity and diabetes therapeutics. Nature Reviews Endocrinology, 18, 195–210 (2022).

7. Kanoski, S. E., & Grill, H. J. Amylin modulation of energy balance: CNS mechanisms and clinical implications. Physiology & Behavior, 100(5), 466–474 (2010).

8. Hay, D. L., & Christopoulos, G. Amylin receptors: Molecular structure, pharmacology, and functional insights. British Journal of Pharmacology, 175(19), 3213–3223 (2018).

9. Bielohuby, M., et al. Amylin and calcitonin receptor pharmacology in energy homeostasis and satiety. Endocrine Reviews, 41(6), 889–920 (2020).

10. Christensen, R. H., et al. Appetite regulation via amylin analogues: Mechanisms and clinical relevance. International Journal of Obesity, 44(7), 1425–1436 (2020).

11. Müller, T. D., Finan, B., Clemmensen, C., et al. Diabetes and obesity therapeutics: ACTH, GLP-1, GIP, amylin, and dual agonist evolution. Nature Medicine, 27(7), 1103–1113 (2021).

12. Finan, B., Yang, B., Ottaway, N., et al. Mechanical synergy: Amylin & GLP-1 receptor co-activation in obesity therapy. Nature Medicine, 21(1), 4–6 (2016).

13. Hjerpsted, J. B., et al. Energy-expenditure and satiety effects of amylin analogues in weight reduction. Obesity Research & Clinical Practice, 13(3), 247–255 (2019).

14. Postic, C., et al. Amylin's impact on glucose regulation and insulin sensitivity. Diabetes Research and Clinical Practice, 150, 198–207 (2019).

15. De Felice, S. L., et al. Pharmacokinetic modeling of long-acting amylin mimetics. Clinical Pharmacokinetics, 58(5), 617–633 (2019).